Buy this biopharmaceutical stock that can rally 25%, says RBC Capital Markets
Insmed’s bronchiectasis treatment in development offers an opportunity for investors, according to RBC Capital Markets. Analyst Leonid Timashev initiated coverage of the biopharmaceutical stock at...